Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation

2003 ◽  
Vol 62 (1-2) ◽  
pp. 61-74 ◽  
Author(s):  
Rolf F. Barth ◽  
Weilian Yang ◽  
Jeffrey A. Coderre
Keyword(s):  
Brain Tumor ◽  
Rat Brain ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Critical Evaluation ◽  
Neutron Capture Therapy ◽  
Tumor Models ◽  
Boron Neutron Capture ◽  
Rat Brain Tumor

scholarly journals The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model

Biology ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 437
Author(s):  
Yusuke Fukuo ◽  
Yoshihide Hattori ◽  
Shinji Kawabata ◽  
Hideki Kashiwagi ◽  
Takuya Kanemitsu ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Boron Concentration ◽  
Tumor Model ◽  
Boron Compound ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Rat Brain Tumor ◽  
Brain Tumor Model

Background: The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine–amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model. Methods: The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time. Results: The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group. Conclusion: BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.

scholarly journals Validation and Comparison of the Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated By Boron-Rich Liposomes in Multiple Murine Tumor Models

2017 ◽  
Vol 10 (4) ◽  
pp. 686-692 ◽  
Author(s):  
Charles A Maitz ◽  
Aslam A Khan ◽  
Peter J Kueffer ◽  
John D Brockman ◽  
Jonathan Dixson ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Therapeutic Efficacy ◽  
Neutron Capture Therapy ◽  
Tumor Models ◽  
Murine Tumor ◽  
Boron Neutron Capture

An improved neutron collimator for brain tumor irradiations in clinical boron neutron capture therapy

1996 ◽  
Vol 23 (12) ◽  
pp. 2051-2060 ◽  
Author(s):  
Hungyuan B. Liu ◽  
Dennis D. Greenberg ◽  
Jacek Capala ◽  
Floyd J. Wheeler
Keyword(s):  
Brain Tumor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Selective ablation of rat brain tumors by boron neutron capture therapy

1994 ◽  
Vol 28 (5) ◽  
pp. 1067-1077 ◽  
Author(s):  
Jeffrey Coderre ◽  
Philip Rubin ◽  
Alan Freedman ◽  
John Hansen ◽  
Thomas S. Wooding ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Rat Brain ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Selective Ablation
Sign in / Sign up

Export Citation Format

Share Document